Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Research Agreement to Promote Development of Monoclonal Antibody-based Therapeutics

By BiotechDaily International staff writers
Posted on 13 Aug 2013
A consortium of biotech companies will promote the use of modified recombinant antibodies for use in the development of monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases.

The cooperating companies include BioWa, Inc. (La Jolla, CA, USA), Lonza (Basel, Switzerland) and Pfizer Inc. (New York, NY, USA).

This arrangement will permit the use of the POTELLIGENT CHOK1SV cell line for research and development leading to production of multiple proprietary antibodies for Pfizer’s product pipeline. POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT Technology with the advantages of Lonza’s industry leading GS Gene Expression System that is based on Lonza’s preeminent host cell line, CHOK1SV.

POTELLIGENT Technology, which was developed by BioWa's mother company Kyowa Hakko Kirin (Tokyo, Japan), involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell.

The POTELLIGENT CHOK1SV cell line retains the desirable features of a high-producing cell line (robust, high yielding, scalable), with the advantage of being a proven bioprocess platform. Antibodies produced by this cell line exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) and can exert potent cytotoxic effects even when their target antigen is low. In addition, they work in whole blood and retain all other desirable features of common antibodies.

“We are pleased that the core value of POTELLIGENT Technology has been recognized by a global pharmaceutical company such as Pfizer, and are excited to work together with Pfizer on their innovative antibody research pipelines,” said Dr. Yasunori Yamaguchi, president and CEO of BioWa.

“The GS System and the CHOK1SV cell line continue to be a gold standard for therapeutic antibody development. We are proud to be able to support Pfizer with this technology for their ongoing development portfolio.” said Karen Fallen, head of licensing at Lonza.

Related Links:

BioWa, Inc.
Lonza
Pfizer Inc.


Channels

Genomics/Proteomics

view channel
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.... Read more

Drug Discovery

view channel

Retinoic Acid Prevents Precancerous Breast Cells from Progressing to Full-Blown Cancer

Retinoic acid, a derivative of vitamin A, was found to prevent pre-cancerous breast cells from progressing to full-blown cancer but did not have any effect on breast tumor cells. Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with a novel breast cancer model that had been developed by treating... Read more

Biochemistry

view channel

Mitochondrial Cause of Aging Can Be Reversed

Researchers have found a cause of aging in lab animals that can be reversed, possibly providing an avenue for new treatments for age-related diseases including type 2 diabetes, cancer, muscle wasting, and inflammatory diseases. The researchers plan to begin human trials late 2014. The study, which was published December... Read more

Therapeutics

view channel

Cytokine Identified That Causes Mucositis in Cancer Therapy Patients

The action of the cytokine interleukin 1-beta (IL-1beta) has been found to underlie the onset of mucositis, a common, severe side effect of chemotherapy and irradiation of cancer patients. Mucositis occurs as a result of cell death in reaction to chemo- or radiotherapy. The mucosal lining of the mouth becomes thin, may... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.